Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0552
D

Failure to Obtain Informed Consent for Psychotropic Medication

Los Angeles, California Survey Completed on 12-23-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to obtain informed consent from the responsible party prior to administering Depakote, an anticonvulsant medication, to a resident diagnosed with schizoaffective disorder, schizophrenia, and depression. The resident was determined to lack the capacity to make healthcare decisions, and a responsible party was designated to make such decisions on their behalf. Despite this, there was no documented verification that the responsible party was informed about the risks, benefits, and alternatives to Depakote before it was administered for mood disorder symptoms, specifically angry outbursts. Interviews with facility staff confirmed that the process for obtaining informed consent required the physician to explain the medication and its effects to the responsible party, with nursing staff responsible for verifying that consent was obtained before administration. Record review showed that while informed consent documentation existed for other antipsychotic medications, none was present for Depakote. Facility policies also required that residents or their representatives be informed and involved in medication management, including the right to refuse treatment, but this process was not followed in this instance.

An unhandled error has occurred. Reload 🗙